Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Bococizumab by Injection Site
NCT02043301Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2014
- Primary completion
- Nov 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bococizumab in hypercholesterolemia (3 arms), sponsored by Pfizer. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinite Time at Day 85 and Maximum Observed Plasma Concentration at Day 85. Started Apr 2014; status: completed.
02
Drugs
bococizumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02043301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02043301.